Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Updated the press releases listing on the page by adding newer announcements (including Dupixent® approval in the U.S., a Phase 3 results update for cemdisiran, and an investor conference presentation). Removed older listed items related to previous approvals/investor presentations and a past press release entry from the current view.
    Difference
    6%
    Check dated 2026-04-23T14:48:13.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Added two new press releases: Regeneron and Telix Announce Strategic Radiopharma Collaboration and Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU). Removed two older press releases: Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders and Dupixent (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS).
    Difference
    6%
    Check dated 2026-04-16T10:40:21.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Added two new press releases on April 2, 2026: 'Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions' and 'EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)'. Removed two older entries: 'Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)' and 'Regeneron Announces Investor Conference Presentations.'
    Difference
    6%
    Check dated 2026-04-09T08:00:07.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    Two new press releases were added to the listing (Q1 2026 financial results and a Japan product approval), and two older February 2026 items were removed.
    Difference
    6%
    Check dated 2026-03-25T20:24:19.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    New March 2026 press releases appear on the page, including Regeneron Science Talent Search 2026 recognition and other updates. Older January 2026 press releases are removed, changing the set of headlines presented.
    Difference
    8%
    Check dated 2026-03-11T17:16:52.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Two new press releases were added to the Press Releases page: 'Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders' (Feb 26, 2026) and 'Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment' (Feb 27, 2026).
    Difference
    2%
    Check dated 2026-03-04T12:55:56.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.